|
| Index | - | P/E | - | EPS (ttm) | -0.92 | Insider Own | 66.81% | Shs Outstand | 1.43M | Perf Week | -54.04% |
| Market Cap | 1.30M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 0.47M | Perf Month | -54.50% |
| Income | - | PEG | - | EPS next Q | - | Inst Own | 2.58% | Short Float / Ratio | 24.89% / 0.13 | Perf Quarter | -71.11% |
| Sales | 4.36M | P/S | 0.30 | EPS this Y | - | Inst Trans | - | Short Interest | 0.12M | Perf Half Y | -88.19% |
| Book/sh | 0.25 | P/B | 3.63 | EPS next Y | - | ROA | - | Target Price | - | Perf Year | -98.07% |
| Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 1.62 - 57.05 | Perf YTD | -72.26% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -98.40% | Beta | - |
| Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | -43.83% | ATR | 0.56 |
| Employees | - | Current Ratio | - | Sales Q/Q | -24.00% | Oper. Margin | - | RSI (14) | 32.55 | Volatility | 85.10% 28.84% |
| Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 15.57 | Prev Close | 1.66 |
| Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 916.51K | Price | 0.91 |
| Recom | - | SMA20 | -53.17% | SMA50 | -67.44% | SMA200 | -89.31% | Volume | 14,267,259 | Change | -45.18% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| G Medical Innovations Holdings Ltd, together with its subsidiaries, an early commercial stage healthcare company, engages in the development of next generation mobile health and telemedicine solutions in the United States, China, and Israel. The company's products include Prizma, a plug-and-play medical device that measures vital signs with electronic medical records functionality and clinical grade reporting standards; and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiogram data continuously for up to 14 days. It also develops Wireless Vital Signs Monitoring System, a solution that provides continuous real time monitoring of vital signs and biometrics. In addition, it offers monitoring services, including independent diagnostic testing facility monitoring and private monitoring services. The company was incorporated in 2014 and is based in Rehovot, Israel. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite